

Special Issue

Reverse Vaccinology and Genomics

Message from the Guest Editor

Novel strategies based on the analysis of the pathogens' genome developed over the last years enable to identify efficient vaccine antigens. These strategies are known under the name of reverse vaccinology. At the beginning, it consisted in manual screening of hundreds of potential proteins of the pathogen. Thereafter in silico analyses, using specific software and databases, helped to identify Open Reading Frames (ORFs) encoding potential vaccine antigens. Thus, only a low number of vaccine candidates has to be evaluated in vivo for their protective potentials. Such studies were first performed to develop new human vaccines. There is a need to develop specific reverse vaccinology tools for veterinary purposes. The aim of this specific issue will be to publish papers describing the development or optimization of human or veterinary vaccines identified through reverse vaccinology strategies. Another part of this issue will be the description of novel reverse vaccinology tools, including those specifically dedicated to veterinary species. A special interest will be on the development of tools potentially detecting T-cell antigens.

Guest Editor

Dr. Daniel Dory

ANSES - French Agency for Food, Environmental and Occupational Health & Safety, Ploufragan-Plouzane-Niort Laboratory, Viral Genetics and Biosafety Unit, 22440 Ploufragan, France

Deadline for manuscript submissions

closed (31 January 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/39606

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).